NCT00143299View on ClinicalTrials.gov

A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

PHASE3CompletedINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

March 31, 2005

Conditions
Smoking Cessation
Interventions
DRUG

varenicline (CP-526,555)

Trial Locations (9)

5011

Pfizer Investigational Site, Woodville South

13210

Pfizer Investigational Site, Syracuse

19438

Pfizer Investigational Site, Harleysville

23249

Pfizer Investigational Site, Richmond

28207

Pfizer Investigational Site, Charlotte

73103

Pfizer Investigational Site, Oklahoma City

80212

Pfizer Investigational Site, Denver

87108

Pfizer Investigational Site, Albuquerque

01757

Pfizer Investigational Site, Milford

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00143299 - A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline | Biotech Hunter | Biotech Hunter